The Economic Impact of Optimizing a COVID-19 Management Protocol in Pre-Existing Cardiovascular Disease Patients
<p>This study answers the question of whether the health care costs of managing COVID-19 in preexisting cardiovascular diseases (CVD) patients increased or decreased as a consequence of evidence-based efforts to optimize the initial COVID-19 management protocol in a CVD group of patients. A re...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , , , , |
| منشور في: |
2023
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513535826984960 |
|---|---|
| author | Dina Abushanab (10696501) |
| author2 | Mohammed Eldebs (17563230) Ahmed Basha (17563233) Lina Naseralallah (14146465) Hadia Kazkaz (17563236) Ahmed Moursi (17563239) Fatima Albazoon (17563242) Omar Wafi (16494868) Saif Badran (16888785) Suhail A.R. Doi (13032075) Somaya Al-Maadeed (5178131) Mohammed Fasihul Alam (6832217) Daoud Al-Badriyeh (832403) |
| author2_role | author author author author author author author author author author author author |
| author_facet | Dina Abushanab (10696501) Mohammed Eldebs (17563230) Ahmed Basha (17563233) Lina Naseralallah (14146465) Hadia Kazkaz (17563236) Ahmed Moursi (17563239) Fatima Albazoon (17563242) Omar Wafi (16494868) Saif Badran (16888785) Suhail A.R. Doi (13032075) Somaya Al-Maadeed (5178131) Mohammed Fasihul Alam (6832217) Daoud Al-Badriyeh (832403) |
| author_role | author |
| dc.creator.none.fl_str_mv | Dina Abushanab (10696501) Mohammed Eldebs (17563230) Ahmed Basha (17563233) Lina Naseralallah (14146465) Hadia Kazkaz (17563236) Ahmed Moursi (17563239) Fatima Albazoon (17563242) Omar Wafi (16494868) Saif Badran (16888785) Suhail A.R. Doi (13032075) Somaya Al-Maadeed (5178131) Mohammed Fasihul Alam (6832217) Daoud Al-Badriyeh (832403) |
| dc.date.none.fl_str_mv | 2023-08-01T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.cpcardiol.2022.101177 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/The_Economic_Impact_of_Optimizing_a_COVID-19_Management_Protocol_in_Pre-Existing_Cardiovascular_Disease_Patients/24745758 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Economics Applied economics Economic Impact COVID-19 Cardiovascular Disease |
| dc.title.none.fl_str_mv | The Economic Impact of Optimizing a COVID-19 Management Protocol in Pre-Existing Cardiovascular Disease Patients |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p>This study answers the question of whether the health care costs of managing COVID-19 in preexisting cardiovascular diseases (CVD) patients increased or decreased as a consequence of evidence-based efforts to optimize the initial COVID-19 management protocol in a CVD group of patients. A retrospective cohort study was conducted in preexisting CVD patients with COVID-19 in Hamad Medical Corporation, Qatar. From the health care perspective, only direct medical costs were considered, adjusted to their 2021 values. The impact of revising the protocol was a reduction in the overall costs in non-critically ill patients from QAR15,447 (USD 4243) to QAR4337 (USD 1191) per patient, with an economic benefit of QAR11,110 (USD 3051). In the critically ill patients, however, the cost increased from QAR202,094 (USD 55,505) to QAR292,856 (USD 80,433) per patient, with added cost of QAR90,762 (USD 24,928). Overall, regardless of critical care status, the optimization of the initial COVID-19 protocols in patients with preexisting CVD did not reduce overall health care costs, but increased it by QAR80,529 (USD 22,117) per patient.</p><h2>Other Information</h2> <p> Published in: Current Problems in Cardiology<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpcardiol.2022.101177" target="_blank">https://dx.doi.org/10.1016/j.cpcardiol.2022.101177</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_22834d89b9d0f71c5d6f13f10a86b774 |
| identifier_str_mv | 10.1016/j.cpcardiol.2022.101177 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/24745758 |
| publishDate | 2023 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | The Economic Impact of Optimizing a COVID-19 Management Protocol in Pre-Existing Cardiovascular Disease PatientsDina Abushanab (10696501)Mohammed Eldebs (17563230)Ahmed Basha (17563233)Lina Naseralallah (14146465)Hadia Kazkaz (17563236)Ahmed Moursi (17563239)Fatima Albazoon (17563242)Omar Wafi (16494868)Saif Badran (16888785)Suhail A.R. Doi (13032075)Somaya Al-Maadeed (5178131)Mohammed Fasihul Alam (6832217)Daoud Al-Badriyeh (832403)Biomedical and clinical sciencesCardiovascular medicine and haematologyEconomicsApplied economicsEconomicImpactCOVID-19Cardiovascular Disease<p>This study answers the question of whether the health care costs of managing COVID-19 in preexisting cardiovascular diseases (CVD) patients increased or decreased as a consequence of evidence-based efforts to optimize the initial COVID-19 management protocol in a CVD group of patients. A retrospective cohort study was conducted in preexisting CVD patients with COVID-19 in Hamad Medical Corporation, Qatar. From the health care perspective, only direct medical costs were considered, adjusted to their 2021 values. The impact of revising the protocol was a reduction in the overall costs in non-critically ill patients from QAR15,447 (USD 4243) to QAR4337 (USD 1191) per patient, with an economic benefit of QAR11,110 (USD 3051). In the critically ill patients, however, the cost increased from QAR202,094 (USD 55,505) to QAR292,856 (USD 80,433) per patient, with added cost of QAR90,762 (USD 24,928). Overall, regardless of critical care status, the optimization of the initial COVID-19 protocols in patients with preexisting CVD did not reduce overall health care costs, but increased it by QAR80,529 (USD 22,117) per patient.</p><h2>Other Information</h2> <p> Published in: Current Problems in Cardiology<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpcardiol.2022.101177" target="_blank">https://dx.doi.org/10.1016/j.cpcardiol.2022.101177</a></p>2023-08-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.cpcardiol.2022.101177https://figshare.com/articles/journal_contribution/The_Economic_Impact_of_Optimizing_a_COVID-19_Management_Protocol_in_Pre-Existing_Cardiovascular_Disease_Patients/24745758CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/247457582023-08-01T00:00:00Z |
| spellingShingle | The Economic Impact of Optimizing a COVID-19 Management Protocol in Pre-Existing Cardiovascular Disease Patients Dina Abushanab (10696501) Biomedical and clinical sciences Cardiovascular medicine and haematology Economics Applied economics Economic Impact COVID-19 Cardiovascular Disease |
| status_str | publishedVersion |
| title | The Economic Impact of Optimizing a COVID-19 Management Protocol in Pre-Existing Cardiovascular Disease Patients |
| title_full | The Economic Impact of Optimizing a COVID-19 Management Protocol in Pre-Existing Cardiovascular Disease Patients |
| title_fullStr | The Economic Impact of Optimizing a COVID-19 Management Protocol in Pre-Existing Cardiovascular Disease Patients |
| title_full_unstemmed | The Economic Impact of Optimizing a COVID-19 Management Protocol in Pre-Existing Cardiovascular Disease Patients |
| title_short | The Economic Impact of Optimizing a COVID-19 Management Protocol in Pre-Existing Cardiovascular Disease Patients |
| title_sort | The Economic Impact of Optimizing a COVID-19 Management Protocol in Pre-Existing Cardiovascular Disease Patients |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Economics Applied economics Economic Impact COVID-19 Cardiovascular Disease |